Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 Sep;16(9):1567-74.
doi: 10.1002/ibd.21193.

Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study

Affiliations
Free PMC article
Randomized Controlled Trial

Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study

Hiroaki Ito et al. Inflamm Bowel Dis. 2010 Sep.
Free PMC article

Abstract

Background: Mesalamine is the first-line drug for the treatment of ulcerative colitis (UC). We directly compared the efficacy and safety of two mesalamine formulations for the induction of remission in patients with UC.

Methods: In a multicenter, double-blind, randomized study, 229 patients with mild-to-moderate active UC were assigned to 4 groups: 66 and 65 received a pH-dependent release formulation of 2.4 g/day (pH-2.4 g) or 3.6 g/day (pH-3.6 g), respectively; 65 received a time-dependent release formulation of 2.25 g/day (Time-2.25 g), and 33 received placebo (Placebo). The drugs were administered three times daily for eight weeks. The primary endpoint was a decrease in the UC disease activity index (UC-DAI).

Results: In the full analysis set (n = 225) the decrease in UC-DAI in each group was 1.5 in pH-2.4 g, 2.9 in pH-3.6 g, 1.3 in Time-2.25 g and 0.3 in Placebo, respectively. These results demonstrate the superiority of pH-3.6 g over Time-2.25 g (P = 0.003) and the noninferiority of pH-2.4 g to Time-2.25 g. Among the patients with proctitis-type UC, a significant decrease in UC-DAI was observed in pH-2.4 g and pH-3.6 g as compared to Placebo, but not in Time-2.25 g. No differences were observed in the safety profiles.

Conclusions: Higher dose of the pH-dependent release formulation was more effective for induction of remission in patients with mild-to-moderate active UC. Additionally, the pH-dependent release formulation was preferable to the time-dependent release formulation for patients with proctitis-type UC (UMIN Clinical Trials Registry, no. C000000288).

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Enrolment, randomization, and follow-up of the study patients.
FIGURE 2
FIGURE 2
Proportion of remission and efficacy. The graphs show proportions of remission and efficacy in each group within 95% CIs. Each graph includes 225 patients for analyses (pH-2.4 g, 66; pH-3.6 g, 64; Time-2.25 g, 63; Placebo, 32). A: The proportion of patients who experienced a remission was 30.3% (CI, 19.6–42.8) in pH-2.4 g, 45.3% (CI, 32.9–58.2) in pH-3.6 g, 28.6% (CI, 17.9–41.3) in Time-2.25 g, and 9.4% (CI, 2.0–25.0) in Placebo. There were statistically significant differences from Placebo in all active-drug groups. B: Efficacy was archived in 45.5% (CI, 33.2–58.1) in pH-2.4 g, 64.1% (CI, 51.1–75.6) in pH-3.6 g, 49.2% (CI, 36.4–62.1) in Time-2.25 g, and 28.1% (CI, 13.8–46.7) in Placebo. There were significant differences from Placebo in both pH-3.6 g and Time-2.25 g.

Similar articles

Cited by

References

    1. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004;99:1371–1385. - PubMed
    1. Carter MJ, Lobo AJ, Travis SP, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53(suppl 5):1–16. - PMC - PubMed
    1. Brogden RN, Sorkin EM. Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease. Drugs. 1989;38:500–523. - PubMed
    1. Myers B, Evans DN, Rhodes J, et al. Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut. 1987;28:196–200. - PMC - PubMed
    1. Mardini HA, Lindsay DC, Deighton CM, et al. Effect of polymer coating on faecal recovery of ingested 5-amino salicylic acid in patients with ulcerative colitis. Gut. 1987;28:1084–1089. - PMC - PubMed

Publication types

MeSH terms

Substances